Belzutifan Treatment Registry for VHL-Related Kidney Cancer
Part of Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This study tracks how well belzutifan (a new medication) works for patients with VHL-spectrum disease, a genetic condition that causes tumors. You'll be monitored over time to see how the drug affects your health and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with VHL-spectrum disease (confirmed by genetic testing or clinical evaluation)
- You and your doctor have already decided to start belzutifan treatment
- You do not have a tumor that needs urgent surgery right now
- If you can become pregnant, you must agree to use reliable contraception during the study
- You do not have uncontrolled serious health conditions (like active infections or severe heart/lung disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special imaging agent that targets a protein found in tumors related to Von Hippel-Lindau (VHL) disease. It may help doctors better detect and monitor these tumors.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
This study is for people who are already taking belzutifan in a related trial (LITESPARK-043) and want to continue treatment for advanced solid tumors or von Hippel-Lindau-related conditions. It tests the safety and effects of long-term use.
This trial tests an oral drug called belzutifan in adolescents with specific types of solid tumors, such as pheochromocytoma/paraganglioma, wild-type gastrointestinal stromal tumors, or tumors linked to von Hippel-Lindau disease. It aims to see if the drug can shrink or control these tumors.
This study looks at how early changes in kidney cells can lead to tumors in people with VHL disease. It may help understand why some people develop kidney cancer and how to prevent it.
Hear when a new VHL - Von Hippel-Lindau Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.